Brief: Biostar Pharma Doses First Patients In Two Phase II/III Global Trials Of Utidelone Capsule (UTD2) For Cancer
15/09/2025 14:03
Sept 15 (Reuters) - Beijing Biostar Pharmaceuticals Co Ltd 2563.HK: BIOSTAR PHARMA SUCCESSIVELY ACHIEVED FIRST PATIENT DOSING FOR TWO PHASE II/III MULTIREGIONAL CLINICAL TRIALS OF UTIDELONE CAPSULE (UTD2) Source text: ID:nPnbYlzMma Further company coverage: 2563.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beijing Biostar Pharmaceuticals
See all newsBrief: Beijing Biostar Pharmaceuticals To Issue 25 MLN New Shares At HK$4.00 Per Share
Brief: Beijing Biostar Pharmaceuticals Says Board Resolves To Repurchase H Shares In Open Market
Brief: Beijing Biostar Pharmaceuticals Posts FY Loss Attributable RMB131.4 Mln
Brief: FDA Grants Orphan Drug Designation To Biostar Pharma's Utidelone
Brief: Biostar Pharma Doses First Patients In Two Phase II/III Global Trials Of Utidelone Capsule (UTD2) For Cancer